| Code | CSB-RA621767MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Neihulizumab, targeting SELPLG (selectin P ligand glycoprotein 1), also known as PSGL-1 or CD162. SELPLG is a cell surface glycoprotein primarily expressed on leukocytes that serves as a high-affinity counter-receptor for P-selectin, E-selectin, and L-selectin. This molecule plays a critical role in mediating leukocyte rolling and tethering to endothelial cells during inflammatory responses and immune cell trafficking. SELPLG is implicated in various pathological conditions including inflammatory diseases, autoimmune disorders, cancer metastasis, and transplant rejection, making it an important therapeutic target for modulating excessive immune responses.
Neihulizumab is a humanized IgG4 monoclonal antibody that binds to SELPLG and has been investigated for its potential to suppress pathological immune cell migration and activation. This biosimilar antibody provides researchers with a valuable tool for investigating SELPLG-mediated adhesion mechanisms, studying leukocyte trafficking pathways, and exploring therapeutic interventions in inflammation-related research models. It supports studies examining selectin-ligand interactions and their role in immune-mediated diseases.
There are currently no reviews for this product.